GlaxoSmithKline (GSK)

41.63 +0.31 (0.75%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/1/19 *Est.)

Latest Headlines

GlaxoSmithKline (GSK:LN) (GSK) PT Raised to GBp1,900 at BofA/Merrill Lynch September 20, 2019 8:48 AM - StreetInsider Microsoft nominates GSK CEO Walmsley to board September 19, 2019 5:00 PM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Sep 17 September 17, 2019 1:26 PM - SEC Filing GlaxoSmithKline (GSK:LN) (GSK) PT Raised to GBp1,900 at BofA/Merrill Lynch September 13, 2019 8:36 AM - StreetInsider GlaxoSmithKline (GSK) announces FDA has approved Nucalafor use in children September 12, 2019 3:50 PM - StreetInsider Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma September 12, 2019 3:48 PM - BizWire Form 6-K GLAXOSMITHKLINE PLC For: Sep 11 September 11, 2019 12:33 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Sep 04 September 4, 2019 1:56 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Sep 04 September 4, 2019 9:51 AM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Sep 04 September 4, 2019 9:38 AM - SEC Filing Societe Generale Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Buy September 3, 2019 11:46 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Sep 03 September 3, 2019 8:34 AM - SEC Filing Citi Resumes GlaxoSmithKline (GSK:LN) (GSK) at Neutral September 3, 2019 3:28 AM - StreetInsider GlaxoSmithKline (GSK:LN) (GSK) PT Raised to GBp1,645 at Deutsche Bank September 2, 2019 8:44 AM - StreetInsider Companies with NDRs 08/29 August 29, 2019 6:40 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Aug 23 August 23, 2019 8:28 AM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Aug 22 August 22, 2019 6:49 AM - SEC Filing ViiV Healthcare Announces Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every 2 Mos. August 22, 2019 5:57 AM - StreetInsider UPDATE: Redburn Reinitiates GlaxoSmithKline (GSK:LN) (GSK) at Buy August 22, 2019 5:32 AM - StreetInsider ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months August 22, 2019 2:17 AM - BizWire Form 6-K GLAXOSMITHKLINE PLC For: Aug 21 August 21, 2019 7:08 AM - SEC Filing JPMorgan Reinstates GlaxoSmithKline (GSK:LN) (GSK) at Neutral August 13, 2019 4:19 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Aug 12 August 12, 2019 11:42 AM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Aug 01 August 1, 2019 1:10 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Aug 01 August 1, 2019 12:13 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Aug 01 August 1, 2019 8:36 AM - SEC Filing Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company August 1, 2019 12:16 AM - BizWire Form 6-K GLAXOSMITHKLINE PLC For: Jul 30 July 30, 2019 1:43 PM - SEC Filing Five Years on, 3.9 Million People in the Developing World Have Access to HIV Treatment Dolutegravir, Thanks to Access-oriented Voluntary Licensing Agreements July 30, 2019 8:57 AM - PR NewsWire Form EFFECT GLAXOSMITHKLINE PLC July 30, 2019 6:02 AM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 29 July 29, 2019 9:52 AM - SEC Filing Pfizer to spinoff, merge off-patent drugs unit with Mylan July 29, 2019 7:01 AM - StreetInsider ViiV Healthcare Submits Regulatory Application to European Medicines Agency for Investigational Cabotegravir to Be Used in Combination With Rilpivirine as the First Monthly, Injectable Treatment for H July 29, 2019 2:06 AM - BizWire UBS Reiterates Neutral Rating on GlaxoSmithKline (GSK) July 25, 2019 5:48 AM - StreetInsider Barclays Reiterates Equalweight Rating on GlaxoSmithKline (GSK) July 25, 2019 5:32 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 24 July 24, 2019 4:59 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 24 July 24, 2019 1:54 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 24 July 24, 2019 12:04 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 24 July 24, 2019 11:34 AM - SEC Filing ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV July 24, 2019 11:06 AM - BizWire ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent July 24, 2019 11:06 AM - BizWire GSK raises 2019 earnings expectations after standout quarter for Shingrix July 24, 2019 7:13 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 24 July 24, 2019 6:38 AM - SEC Filing Drugmaker GSK ends chairman search with HSBC's Symonds July 24, 2019 5:11 AM - StreetInsider GlaxoSmithKline (GSK) calls active into quarterly results July 23, 2019 10:59 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 22 July 22, 2019 12:38 PM - SEC Filing ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019 July 22, 2019 12:07 PM - BizWire Form F-6 GLAXOSMITHKLINE PLC Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary July 19, 2019 2:03 PM - SEC Filing As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff July 16, 2019 7:09 PM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 15 July 15, 2019 5:28 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 15 July 15, 2019 5:08 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 15 July 15, 2019 2:07 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 15 July 15, 2019 10:30 AM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 15 July 15, 2019 8:12 AM - SEC Filing Barclays Reiterates Equalweight Rating on GlaxoSmithKline (GSK) July 15, 2019 3:04 AM - StreetInsider GSK in talks to name HSBC's Symonds as its next chairman: Bloomberg July 14, 2019 2:41 PM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 12 July 12, 2019 1:13 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 12 July 12, 2019 1:04 PM - SEC Filing UBS Reiterates Neutral Rating on GlaxoSmithKline (GSK) July 11, 2019 4:46 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 10 July 10, 2019 12:00 PM - SEC Filing European Commission approves GlaxoSmithKline's (GSK) acquisition of Pfizer's (PFE) Consumer Health Business, subject to conditions July 10, 2019 11:59 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 10 July 10, 2019 6:17 AM - SEC Filing GSK, Pfizer (PFE) & Shionogi Ltd. Joint-Owned Company, ViiV Healthcare, Reports Phase III TANGO Study Meets Primary Endpoint July 10, 2019 6:09 AM - StreetInsider ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switch July 10, 2019 2:16 AM - BizWire ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patient July 10, 2019 2:15 AM - BizWire U.S. seeks extradition of Chinese researcher in drug secrets theft July 8, 2019 6:09 AM - StreetInsider GlaxoSmithKline (GSK) option implied volatility low July 8, 2019 5:45 AM - StreetInsider GlaxoSmithKline (GSK:LN) (GSK) PT Raised to GBp1,575 at Deutsche Bank July 8, 2019 4:02 AM - StreetInsider Form 6-K GLAXOSMITHKLINE PLC For: Jul 03 July 3, 2019 7:59 AM - SEC Filing ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection July 3, 2019 4:19 AM - BizWire *Form 11-K GLAXOSMITHKLINE PLC For: Dec 31 July 2, 2019 5:12 PM - SEC Filing *Form 11-K GLAXOSMITHKLINE PLC For: Dec 31 July 2, 2019 5:11 PM - SEC Filing Form 6-K GLAXOSMITHKLINE PLC For: Jul 01 July 1, 2019 10:46 AM - SEC Filing UBS Reiterates Neutral Rating on GlaxoSmithKline (GSK) July 1, 2019 5:43 AM - StreetInsider Full Article List